Spectral-domain oct predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion
International Journal of Development Research
Spectral-domain oct predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion
Received 14th October, 2019; Received in revised form 03rd November, 2019; Accepted 11th December, 2019; Published online 29th January, 2020
Copyright © 2020, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled “Spectral-domain OCT predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion” published by Yiu et al. in Ophthalmology Retina 2020;4(1):67-76. Published online August 28, 2019.The conclusion of this study was that none of the imaging biomarkers showed an independent association with visual outcomes after 7 monthly ranibizumab injections in both central and branch retinal vein occlusions. However, the validation, extrapolation, and generalizability of the authors’ finding can be made only by statistical analyses including all the missing baseline potential predictive factors mentioned by us in addition to the baseline characteristics already evaluated in this study, serving to identify all the key metrics (including the SD-OCT putative biomarkers) of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusions.
